Overview of Halovate-F

Quick Facts

Property	Description
Active ingredient	Fusidic Acid, Ulobetasol (Halobetasol)
Form	Emollient Cream
Pharmacological class	Topical Antibiotic, Ultra-High Potency Corticosteroid
General use	Managing inflamed skin with bacterial involvement
Origin	Synthetic and Fermentation-derived

Halovate-F is a prescription-only combination medication for topical use that integrates two distinct active pharmaceutical ingredients: the antibiotic Fusidic Acid and the high-potency corticosteroid Ulobetasol (also known as Halobetasol propionate). This formulation is typically presented as an emollient cream, specifically designed for external application to the skin. This dual-component preparation is used by medical professionals for its role in providing a rapid, coordinated response to skin conditions where both severe inflammation and the presence of susceptible bacteria are factors.

What Type of Medicine is Halovate-F?

Halovate-F is classified as a dual-action topical preparation that contains two active components designed to be applied directly to the skin's surface. The preparation is considered a combination product because it merges Fusidic Acid, a fermentation-derived antibiotic, with Ulobetasol, a highly potent synthetic corticosteroid. Ulobetasol propionate is a Class I corticosteroid, classifying it among the most potent topical steroids available. This classification means the medicine is designed for powerful and rapid action on inflammation.

Understanding the Dual Composition: Fusidic Acid and Ulobetasol

The medicine's active core consists of Fusidic Acid and Ulobetasol, which belong to the Topical Antibiotic (Fusidane class) and Ultra-High Potency Corticosteroid classes, respectively. Fusidic Acid is valued for its specific mechanism of action against common skin pathogens; it works by inhibiting bacterial protein synthesis, a mechanism that helps control the local bacterial population. The Ulobetasol component exerts a powerful anti-inflammatory and immunosuppressive effect on the skin, reducing redness and swelling. This composition is suspended within a pharmaceutical vehicle, typically an emollient cream base, which facilitates absorption and provides a soothing effect beneficial for dry or damaged skin.

What is the General Purpose of this Combined Therapy?

The general purpose of Halovate-F is to achieve dual-action relief by rapidly reducing the physical symptoms of severe inflammation while simultaneously managing the local bacterial population. This strategic combination provides a focused, high-level intervention, typically used in scenarios where a pre-existing inflammatory skin condition, such as infected dermatitis, has developed a bacterial component. The powerful anti-inflammatory action of the Ulobetasol component quickly calms intense symptoms like swelling and itching, while the Fusidic Acid component ensures that any associated bacterial contamination or secondary infection is controlled.

Regulatory References

NIH: Halobetasol Propionate Cream (DailyMed)

What side effects are possible with Halovate-F?

Possible side effects and safety information

The safety profile of Halovate-F is structured by the properties of its two active ingredients: the topical antibiotic Fusidic Acid and the ultra-high potency corticosteroid, Ulobetasol (Halobetasol propionate). Adverse reactions are typically categorized by frequency and the body system affected, according to official regulatory documentation.

Local reactions are the most Common documented adverse effects (ge 1/100 to < 1/10), which include stinging, burning, and itching at the application site. Less frequent reactions (Uncommon or rarer) may involve rash, irritation, skin atrophy (thinning), striae (stretch marks), and hypopigmentation.

Due to the potent nature of the corticosteroid component, systemic absorption is a major safety consideration, particularly with extensive or prolonged use. Documented serious adverse reactions linked to this absorption include Hypothalamic-Pituitary-Adrenal (HPA)-axis suppression and manifestations of Cushing's syndrome. Serious effects involving the eyes, such as glaucoma or cataracts, are also documented, especially with long-term exposure or application near the eyes.

Population-specific safety considerations include an official note that pediatric patients (under 12 years) are at a significantly greater risk for systemic toxicity, including HPA-axis suppression, due to a higher ratio of skin surface area to body mass. Use in this population is generally not recommended in official labeling. Additionally, use on the face, underarms, or groin area is restricted, as is the use of occlusive (airtight) dressings, due to the heightened risk of both local and systemic adverse effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The risk of acute, massive overdose from topical application of Halovate-F (Halobetasol Propionate) is considered unlikely. However, overdose resulting in systemic toxicity can occur with prolonged, excessive use, especially when applied to large areas of the body, to broken skin, or under occlusive dressings.

Documented Overdose Presentation

The primary danger from overdose or chronic overexposure is the systemic absorption of the potent corticosteroid, which may lead to Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. This is a potentially reversible condition. Continued excessive use may cause manifestations of Cushing's syndrome, hyperglycemia (high blood sugar), and glucosuria (sugar in the urine).

Children are notably more susceptible to systemic toxicity and HPA axis suppression due to their higher skin surface area-to-body weight ratio. Prolonged exposure in pediatric patients may impact growth and weight gain.

Required Emergency Actions

If the medication is accidentally ingested, or if you suspect an overdose has occurred, you must seek immediate emergency medical attention, regardless of the presence of symptoms.

If you have applied an excessive amount topically, the official guidance is to simply wipe the excess medication off the skin with a clean cloth or tissue. Do not apply extra quantities to compensate for a missed dose or to accelerate results. If any unusual or severe systemic reactions are noticed after use, contact a healthcare provider immediately.

Therapeutic Uses of Halovate-F

What Halovate-F Treats: Main Uses and Benefits

The primary therapeutic role of Halovate-F is in symptomatic management for complex skin conditions that may require a dual-action approach, involving severe inflammation and associated bacterial infection. This type of formulation is used for the treatment of acute and chronic infected eczematous dermatitis and similar dermatoses.

This medication is commonly applied in clinical settings involving acute or episodic symptom patterns. It is relevant for easing challenging manifestations across conditions such as infected eczema, infected dermatitis, and infected psoriasis, as well as localized lesions like folliculitis and impetigo.

The medication helps address clusters of pronounced symptoms, including significant swelling, intense redness, and disruptive itching, providing short-term symptomatic support. This may assist with maintaining functional stability and helps improve day-to-day comfort during periods of heightened symptoms.

Quick Fact: Relief for Severe Inflammation and Infection

Symptom Domain	General Benefit
Intense Itching & Swelling	Contributes to improved comfort and eases physical distress.
Infected Dermatoses	Supports the patient by managing inflammation and addressing bacterial contamination.
Acute Flare-ups	Provides supportive relief when symptoms interfere with routine activities.

Regulatory References

acute and chronic infected eczematous dermatitis

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Halovate-F — Official Regulatory Information

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults and children 12 years of age and older are the populations for whom use is generally established, typically limited to a maximum of two consecutive weeks.
Populations for whom use is not recommended (if applicable)	Children under 12 years of age; safety and effectiveness have not been established. Treatment beyond two consecutive weeks is not recommended for any patient.
Populations for whom use is contraindicated	Patients with hypersensitivity to any component. Contraindicated in primary cutaneous infections caused by viruses (e.g., Herpes simplex), fungi, or yeast. Contraindicated in patients with rosacea or perioral dermatitis.
Age-related eligibility rules	Pediatric Use: Not established or not recommended in patients under 12 years of age. Geriatric Use: No specific dosage adjustment is noted, but caution is advised.
Condition-specific eligibility rules	Use requires caution in patients with Cushing’s syndrome, diabetes, or hyperglycemia, as the corticosteroid may worsen these conditions.
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus (Category C). Lactation/Breastfeeding: Caution is advised; avoid application to the breast/nipple area.
Eligibility-related restrictions	Use is avoided on the face, groin, or axillae (armpits). Treatment with occlusive dressings is generally not recommended. The total dosage should not exceed 50 g/week.

Eligibility Classifications (High-Level)

Category	Official Regulatory Statement
Eligibility severity classification (as defined in official documents)	Contraindicated (Absolute Prohibition); Not Recommended (Age-based exclusion); Use with Caution (Comorbidity/Physiological state restriction).
Regulatory basis (EMA / FDA / etc.)	FDA and similar National Health Authority prescribing information for the combined and individual active ingredients.
Eligibility-context constraints (as defined in official documents)	Duration Restriction (Maximum 2 consecutive weeks); Site Restriction (Avoid face, groin, axillae); Dosage Restriction (Maximum 50 grams per week).

Resulting Eligibility Structure

Official eligibility statements:

Contraindicated for patients with hypersensitivity, viral or fungal primary skin infections, rosacea, or perioral dermatitis.
Use is not recommended in the pediatric population under 12 years of age due to unestablished safety.
The medicine must be used for no longer than two consecutive weeks and should not exceed 50 grams per week in all eligible patients.

Connection to the overall eligibility profile: Regulatory documents strictly define who can and cannot use this medicine primarily through the constraints of the ultra-high-potency corticosteroid component, imposing absolute contraindications based on pre-existing skin conditions or infections. These documents also establish clear age-based exclusions for children under 12 and define specific limitations regarding the duration of use and anatomical area of application for all approved populations.

What should I know about interactions with other medicines?

Contraindicated Combinations and Timing Rules

Co-administration with Statins (HMG-CoA reductase inhibitors), such as simvastatin, is formally contraindicated due to the serious, regulatory-documented risk of rhabdomyolysis associated with the Fusidic Acid component. This interaction is rooted in the inhibition of OATP1B1 and OATP1B3 transporters, which leads to increased Statin plasma concentrations. Statin treatment must be discontinued throughout the course of Halovate-F therapy and should not be resumed until seven days after the final dose of the antibiotic.

Pharmacodynamic and Exposure-Modifying Interactions

The use of this product alongside other corticosteroid-containing products is documented to increase the total systemic exposure to the highly potent Ulobetasol component. Furthermore, the product carries risks for pharmacodynamic interactions with several medicinal classes. The systemic absorption of the Ulobetasol component may antagonize insulin action, posing a documented risk of hyperglycemia when co-administered with Antidiabetic Agents. The combination with Oral Anticoagulants (coumarin derivatives) may also alter the anticoagulant effect, requiring appropriate monitoring.

Population-Specific Cautions

Regulatory documents note that pediatric patients are at a greater risk of systemic toxicity from topical corticosteroids, amplifying the severity of any exposure-altering interaction. Caution is also noted for patients with hepatic impairment.

Mechanism of Action

The effect of Halovate-F is achieved through the coordinated action of its two components, engaging two distinct mechanisms: modulation of inflammatory signaling and inhibition of bacterial growth.

️ Modulation of Inflammatory Cascades

The Ulobetasol component, a synthetic corticosteroid, acts as an agonist at the Glucocorticoid Receptor (GR), initiating an intracellular cascade that modulates the host's physiological response . This mechanism blocks the Arachidonic Acid Cascade by inhibiting the PLA2 enzyme and directly suppressing the gene expression of pro-inflammatory mediators. The resulting physiological change is a reduction in local vasodilation and capillary permeability, which limits fluid exudation into the tissue.

Targeted Interference with Bacterial Protein Synthesis

The Fusidic Acid component exerts its effect by acting on bacterial metabolism. It functions as an inhibitor by binding to the bacterial Elongation Factor G (EF-G) complex on the 70S Ribosome . This interference prevents the translocation step required for protein synthesis, thereby halting the bacteria's ability to synthesize proteins. This mechanism is primarily effective against Gram-positive bacteria and results in the cessation of growth for susceptible organisms.

Dosage and Administration Information

How to Use Halovate-F

The usage of Halovate-F, a combination containing an ultra-high potency corticosteroid (Halobetasol Propionate) and an antibiotic (Fusidic Acid), is subject to specific constraints to control exposure and maximize localized effect.

Administration and Dosage

Category	Instruction Principle
Route of Administration	Application is restricted to topical (cutaneous) use only. The cream is not intended for use in the eyes, mouth, or internally.
Application Frequency	The preparation is typically applied to the affected skin area twice daily.
Dosing Limit	The medication should be applied as a thin layer, and the total amount used is limited to 50 grams per week.

Duration and Procedural Constraints

The treatment course for this combination is defined as short-term due to the potency of the corticosteroid component. Continuous application must not exceed two consecutive weeks. Furthermore, therapy should be discontinued once the condition is controlled.

Key procedural constraints are observed during application. The cream should not be covered with occlusive dressings (like bandages or wraps), as this can increase absorption. Application is restricted and must be avoided on sensitive skin areas, including the face, groin, and axillae. Users are instructed to wash their hands thoroughly after applying the medication, unless the hands are the area being treated. Use in pediatric patients under 12 years of age is not recommended.

These guidelines define the standardized approach for the use of this medicine, ensuring its potent components are administered within established parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Halovate-F

Research Evidence for the Combined Therapy

Halovate-F combines an ultra-high potency corticosteroid (Ulobetasol/Halobetasol) with the antibiotic Fusidic Acid. This dual formulation was studied in research examining skin conditions where both severe inflammation and the involvement of bacteria are factors. Research explored outcomes linked to inflammatory states (such as redness and swelling) and bacteriological measures (such as the presence of common skin pathogens like Staphylococcus aureus).

The foundation of the evidence relies on Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies are used in research exploring how the combination compares against its components or vehicle, which contribute to the broader evidence landscape for topical antibiotic-steroid combinations.

Studies for Infected Steroid-Responsive Dermatoses

Research for the combination was evaluated in trials exploring conditions such as secondarily infected dermatitis. These trials generally included adult patients whose conditions presented with clinically apparent infection. Research examined primary outcomes related to physical sign evolution and symptom intensity, often measured using the Investigator’s Global Assessment (IGA) scale. Findings describe patterns observed in studies comparing the full combination to the steroid alone. However, in some studies, evidence quality varies, and comparative evidence is lacking regarding the additional effect of the antibiotic over the corticosteroid component alone.

Long-Term Evidence and Durability of Response

Studies typically monitored responses over short-term acute treatment phases, often limited to two to four weeks; follow-up durations were limited. What remains uncertain: There is limited information for long-term outcomes regarding the durability of the reported response or the maintenance of changes after treatment is concluded.

Research Gaps and Areas of Uncertainty

The primary body of evidence was observed in trials that included adult patients. What remains uncertain: Data for certain groups remain insufficient. For instance, subgroup findings are uncertain for children with infected eczema, and comparative evidence is lacking for older adults. Uncertainty also relates to the comparative evidence regarding the antibiotic component when the presence of a secondary bacterial infection is subclinical or uncertain.

Key Studies & References Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NICE Guideline NG190)

Frequently Asked Questions (FAQ)

Common questions about Halovate-F (FAQ)

Q: Is it common to feel a stinging sensation when first using Halovate-F?

A: Regulatory-aligned patient information describes that a temporary sensation such as burning, stinging, or itching may occur when the medicine is first applied to the skin. This initial reaction is described as generally resolving as the skin adjusts to the product.

Q: Can I use other skin creams or cosmetics while using Halovate-F?

A: Official instructions note restrictions regarding covering the treated area with occlusive (airtight) dressings. Regulatory labeling, however, does not provide general guidance on all other non-occlusive skin creams or cosmetics.

Q: Is Halovate-F absorbed into the bloodstream?

A: Studies and official information indicate that the active components can be absorbed from the skin and enter the systemic circulation. However, the amount that enters the circulation is typically described as small, often measured as less than six percent of the applied dose.

Q: Can Halovate-F be purchased over the counter in any country?

A: Halovate-F is described as a prescription-only medication (POM) in major regulatory documents across different regions. This classification restricts its availability to dispensing only with a formal prescription.

Q: Can Halovate-F affect the healing time of wounds?

A: Official safety information indicates that the chance of certain local side effects may be increased if the medicine is applied to large sores, broken skin, or severe skin injuries. This caution is related to the potential for increased absorption when the medicine is applied to compromised skin.

Q: How quickly does Halovate-F usually start to work?

A: Official product information indicates that improvement in the specific skin condition being treated is expected to be observed during the first two weeks of treatment.

Q: What happens if I forget to use Halovate-F?

A: If an application is missed, it should be used as soon as it is remembered. If it is almost time for the next scheduled application, the missed dose should be skipped. Regulatory advice indicates that applying a double amount to compensate for a missed dose is not advised.

Q: Are there specific food or drink interactions with Halovate-F?

A: According to the official product safety advice, there are no specific food or drink interactions formally documented for Halovate-F.

Q: Can Halovate-F be used by people with kidney problems?

A: Official safety advice notes that patients with a history of kidney diseases should provide this information to their healthcare provider. This information is noted in safety advice as a consideration for the healthcare professional.

Q: Why is Halovate-F only available with a prescription?

A: Halovate-F is a prescription-only medicine because one of its active components, the corticosteroid Ulobetasol (Halobetasol), is classified as a super-high potency (Class I) topical steroid. The classification indicates the necessity for professional guidance to monitor use and adherence to treatment duration limits.

Q: Do weather conditions affect how Halovate-F should be stored or used?

A: Storage instructions require that Halovate-F must be kept at a controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). It must be kept away from heat, moisture, and direct light, and it must not be frozen.

Q: What if my skin condition gets worse after starting Halovate-F?

A: Official guidance indicates that if the skin condition does not begin to improve or if the symptoms worsen during the first two weeks of treatment, reassessment of the diagnosis by a healthcare professional may be appropriate.

Q: What kind of specialist usually prescribes Halovate-F?

A: Topical corticosteroids of this potency class are commonly noted in regulatory-aligned literature as often being prescribed by specialists such as dermatologists for the management of severe inflammatory skin conditions.

Q: Does Halovate-F contain any parabens or common allergens?

A: The inactive ingredients used in the cream formulation can vary by manufacturer. While some formulations of the Halobetasol component are described as free of parabens, official ingredient lists for components often mention preservatives such as diazolidinyl urea and methylisothiazolinone.

Q: Does Halovate-F contain lanolin or other animal-derived ingredients?

A: Information on certain formulations of the Halobetasol component indicates that they are described as Lanolin Free. Specific details about all inactive ingredients or whether they are animal-derived are typically listed on the full product ingredient list provided by the manufacturer.

Q: Are there specific activities or clothing materials to avoid while using Halovate-F?

A: Regulatory safety advice for the Fusidic Acid component notes that the cream can dry onto clothing and bedding, potentially making them more likely to catch fire. Users are therefore advised to avoid smoking or going near naked flames due to this potential increased fire risk.

Q: What is the half-life of Halovate-F's active ingredients?

A: The half-life of the Fusidic Acid component when absorbed into the body is cited in pharmacological literature as approximately 5 to 6 hours in adults. Information regarding the half-life of the Halobetasol component is typically detailed in specialized pharmacokinetics reports.

Q: Is Halovate-F safe to use with alcohol consumption?

A: No specific interactions between the components of Halovate-F and alcohol consumption are formally documented in official safety advice.

Q: What happens if I accidentally swallow a small amount of Halovate-F?

A: The medicine is strictly for external, topical use. Regulatory documents advise against letting the product enter the mouth or be swallowed. While accidental, small-amount ingestion is generally described in patient information as unlikely to cause harm, the medicine is strictly advised against ingestion.

Q: What does the 'F' stand for in Halovate-F?

A: The 'F' in Halovate-F is understood to represent the Fusidic Acid component, which is the topical antibiotic. This component is combined with the corticosteroid Ulobetasol (Halobetasol) in the formulation.

Q: What happens if I miss a few applications of Halovate-F?

A: If an application is missed, it should be used as soon as it is remembered. If it is almost time for the next scheduled application, the missed dose should be skipped. Regulatory advice indicates that applying a double amount to compensate for a missed dose is not advised.

How should Halovate-F be stored and disposed of?

How to Store and Dispose of Halovate-F Cream

The storage and disposal of Halovate-F (Halobetasol Propionate and Fusidic Acid) cream are governed by official regulatory labeling to maintain stability and ensure safety.

Storage Requirements

The cream must be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). Storage must be in a closed container and away from heat, moisture, and direct light. It is strictly required to not freeze the product.

Child Safety and Stability

Halovate-F must be kept out of the sight and reach of children and pets. Once the tube is initially opened, the medicine has a limited in-use stability period, and any unused product must typically be discarded after 4 weeks.

Disposal Instructions

Unused or expired Halovate-F must not be thrown away via household trash or wastewater. Disposal should be done in accordance with local regulatory requirements, and guidance should be sought from a healthcare professional or pharmacist.

Halovate-F